What's Happening?
Nomic Bio has published its nELISA technology in Nature Methods, detailing a high-throughput, high-plex immunoassay platform that maintains specificity at scale. The technology enables multiplexed, absolute quantification of proteins with 99.99% specificity and
0.1g/mL sensitivity, processing over 1000 samples per day. The publication coincides with the release of a 1.4 million-data-point PBMC cytokine perturbation dataset in the Nomic Portal, allowing for interactive exploration and analysis of proteomic data. The study demonstrates nELISA’s compatibility with assay modalities beyond abundance, including protein modifications and protein-protein interactions.
Why It's Important?
The nELISA technology represents a significant advancement in proteomics, offering a scalable and systematic approach to protein quantification that complements transcriptomic data. By providing a direct, functional readout of immune regulation, nELISA enhances the understanding of cell states and accelerates drug discovery applications. The technology’s high throughput and specificity could revolutionize proteomic screening, making it more accessible and routine for researchers and pharmaceutical companies, potentially leading to faster development of new therapies and biomarkers.
What's Next?
Nomic Bio plans to scale the nELISA platform to a 1,000-plex offering, designed for broad discovery at disruptive cost and unmatched throughput. The Perturb-PBMC dataset is available for interactive exploration in the Nomic Portal, enabling rich multidimensional analysis and customizable visualizations. The company aims to integrate proteomics across all stages of drug and biomarker development, making it ubiquitous for modern biology.
Beyond the Headlines
The publication of nELISA technology highlights the growing importance of proteomics in understanding biological processes and developing new therapies. By providing a scalable and cost-effective solution for protein quantification, Nomic Bio is positioned to drive innovation in the field, potentially leading to new insights into disease mechanisms and personalized medicine approaches.
